» Articles » PMID: 37711665

PROBABILISTIC LEARNING OF TREATMENT TREES IN CANCER

Overview
Journal Ann Appl Stat
Date 2023 Sep 15
PMID 37711665
Authors
Affiliations
Soon will be listed here.
Abstract

Accurate identification of synergistic treatment combinations and their underlying biological mechanisms is critical across many disease domains, especially cancer. In translational oncology research, preclinical systems such as patient-derived xenografts (PDX) have emerged as a unique study design evaluating multiple treatments administered to samples from the same human tumor implanted into genetically identical mice. In this paper, we propose a novel Bayesian probabilistic tree-based framework for PDX data to investigate the hierarchical relationships between treatments by inferring treatment cluster trees, referred to as treatment trees (R-tree). The framework motivates a new metric of mechanistic similarity between two or more treatments accounting for inherent uncertainty in tree estimation; treatments with a high estimated similarity have potentially high mechanistic synergy. Building upon Dirichlet Diffusion Trees, we derive a closed-form marginal likelihood encoding the tree structure, which facilitates computationally efficient posterior inference via a new two-stage algorithm. Simulation studies demonstrate superior performance of the proposed method in recovering the tree structure and treatment similarities. Our analyses of a recently collated PDX dataset produce treatment similarity estimates that show a high degree of concordance with known biological mechanisms across treatments in five different cancers. More importantly, we uncover new and potentially effective combination therapies that confer synergistic regulation of specific downstream biological pathways for future clinical investigations. Our accompanying code, data, and shiny application for visualization of results are available at: https://github.com/bayesrx/RxTree.

References
1.
Zhang X, Claerhout S, Prat A, Dobrolecki L, Petrovic I, Lai Q . A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013; 73(15):4885-97. PMC: 3732575. DOI: 10.1158/0008-5472.CAN-12-4081. View

2.
Yoshida G . Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020; 13(1):4. PMC: 6947974. DOI: 10.1186/s13045-019-0829-z. View

3.
Oh D, Bang Y . HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol. 2019; 17(1):33-48. DOI: 10.1038/s41571-019-0268-3. View

4.
Yuan Y, Wen W, Yost S, Xing Q, Yan J, Han E . Combination therapy with BYL719 and LEE011 is synergistic and causes a greater suppression of p-S6 in triple negative breast cancer. Sci Rep. 2019; 9(1):7509. PMC: 6525251. DOI: 10.1038/s41598-019-43429-7. View

5.
Bayat Mokhtari R, Homayouni T, Baluch N, Morgatskaya E, Kumar S, Das B . Combination therapy in combating cancer. Oncotarget. 2017; 8(23):38022-38043. PMC: 5514969. DOI: 10.18632/oncotarget.16723. View